Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.45
  • Today's Change-0.06 / -1.71%
  • Shares traded53.62m
  • 1 Year change-3.36%
  • Beta0.7445
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy10
Outperform15
Hold1
Sell0
Strong Sell0

Share price forecast in CNY

The 21 analysts offering 12 month price targets for Sino Biopharmaceutical Ltd have a median target of 4.40, with a high estimate of 7.00 and a low estimate of 3.00. The median estimate represents a 27.45% increase from the last price of 3.45.
High102.8%7.00
Med27.4%4.40
Low-13.0%3.00

Dividends

In 2023, Sino Biopharmaceutical Ltd reported a dividend of 0.05 CNY, which represents a 57.11% decrease from last year. The 14 analysts covering the company expect dividends of 0.06 CNY for the upcoming fiscal year, an increase of 25.41%.
Div growth (TTM)-57.11%
More ▼

Earnings history & estimates in CNY

On Aug 31, 2021, earnings of 0.33 per share. This result exceeded the 0.11 consensus of the 2 analysts covering the company
Average growth rate+91.39%
Sino Biopharmaceutical Ltd reported annual 2023 earnings of 0.137 per share on Mar 28, 2024.
Average growth rate-4.39%
More ▼

Revenue history & estimates in CNY

of 7.60bn. This missed the 8.20bn estimate of the one analyst following the company.
Average growth rate+9.05%
Sino Biopharmaceutical Limited had revenues for the full year 2023 of 26.20bn. This was 8.97% below the prior year's results.
Average growth rate+2.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.